B-cell maturation antigen (BCMA) is the leading target for CAR-T therapy, which has been successful in the treatment of relapsed/refractory MM.
Antigen escape, the poor persistence of CAR-T cells, and the complicated tumor microenvironment remain a challenge to a significant population of MM patients who experience relapse after anti-BCMA CAR-T cell therapy. Broad clinical application of CAR-T cell therapy is also hampered by the high cost and time-consuming nature of the manufacturing processes. There are several potential strategies under investigation to overcome these challenges.
In patients with relapsed or refractory MM, the use of a bispecific antibody that binds to both BCMA and CD3 to redirect T cells to MM cells shows promising efficacy. Other potential targets either for single-target or dual-target CAR-T are also being studied.
Learn more about antibody-drug conjugates in MM.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Joshua Richter, Emmanuel C. Besa. Fast Five Quiz: Multiple Myeloma Management - Medscape - May 16, 2023.